Dr Dmitry Pshezhetskiy

Publications


Journals

  • Nunes J; Naymark M; Sauer L; Muhammad A; Keun H; Sturge J; Stebbing J; Waxman J; et alPchejetski D. (7 Feb 2012). Circulating sphingosine-1-phosphate and erythrocyte sphingosine kinase-1 activity as novel biomarkers for early prostate cancer detection. Br J Cancer. DOI.
  • Pchejetski D; Foussal C; Alfarano C; Lairez O; Calise D; Guilbeau-Frugier C; Schaak S; Seguelas MH; et alWanecq E; Valet P; Parini A; Kunduzova O. (25 Oct 2011). Apelin prevents cardiac fibroblast activation and collagen production through inhibition of sphingosine kinase 1. Eur Heart J. DOI.
  • Pchejetski D; Böhler T; Stebbing J; Waxman J. (Oct 2011). Therapeutic potential of targeting sphingosine kinase 1 in prostate cancer. Nat Rev Urol. 8:569-678. DOI.
  • Stebbing J; Sharma A; North B; Athersuch TJ; Zebrowski A; Pchejetski D; Coombes RC; Nicholson JK; et alKeun HC. (4 Aug 2011). A metabolic phenotyping approach to understanding relationships between metabolic syndrome and breast tumour responses to chemotherapy. Ann Oncol. DOI.
  • Malavaud B; Pchejetski D; Mazerolles C; de Paiva GR; Calvet C; Doumerc N; Pitson S; Rischmann P; et alCuvillier O. (Dec 2010). Sphingosine kinase-1 activity and expression in human prostate cancer resection specimens. Eur J Cancer. 46:3417-3424. DOI.
  • Pchejetski D; Bohler T; Brizuela L; Sauer L; Doumerc N; Golzio M; Salunkhe V; Teissié J; et alMalavaud B; Waxman J; Cuvillier O. (1 Nov 2010). FTY720 (fingolimod) sensitizes prostate cancer cells to radiotherapy by inhibition of sphingosine kinase-1. Cancer Res. 70:8651-8661. DOI.
  • Pchejetski D; Nunes J; Coughlan K; Lall H; Pitson SM; Waxman J; Sumbayev VV. (Feb 2011). The involvement of sphingosine kinase 1 in LPS-induced Toll-like receptor 4-mediated accumulation of HIF-1α protein, activation of ASK1 and production of the pro-inflammatory cytokine IL-6. Immunol Cell Biol. 89:268-274. DOI.
  • Henry NL; Pchejetski D; A'Hern R; Nguyen AT; Charles P; Waxman J; Li L; Storniolo AM; et alHayes DF; Flockhart DA; Stearns V; Stebbing J. (27 Jul 2010). Inflammatory cytokines and aromatase inhibitor-associated musculoskeletal syndrome: a case-control study. Br J Cancer. 103:291-296. DOI.
  • Pchejetski D; Nunes J; Sauer L; Sidhu J; Sharma A; Keun HC; Waxman J; Stebbing J. (Nov 2010). Circulating sphingosine-1-phosphate inversely correlates with chemotherapy-induced weight gain during early breast cancer. Breast Cancer Res Treat. 124:543-549. DOI.
  • Keun HC; Sidhu J; Pchejetski D; Lewis JS; Marconell H; Patterson M; Bloom SR; Amber V; et alCoombes RC; Stebbing J. (1 Nov 2009). Serum Molecular Signatures of Weight Change during Early Breast Cancer Chemotherapy. CLIN CANCER RES. 15:6716-6723. DOI.
  • Sauer L; Nunes J; Salunkhe V; Skalska L; Kohama T; Cuvillier O; Waxman J; Pchejetski D. (1 Dec 2009). Sphingosine kinase 1 inhibition sensitizes hormone-resistant prostate cancer to docetaxel. Int J Cancer. 125:2728-2736. DOI.
  • Guillermet-Guibert J; Davenne L; Pchejetski D; Saint-Laurent N; Brizuela L; Guilbeau-Frugier C; Delisle MB; Cuvillier O; et alSusini C; Bousquet C. (Apr 2009). Targeting the sphingolipid metabolism to defeat pancreatic cancer cell resistance to the chemotherapeutic gemcitabine drug. MOL CANCER THER. 8:809-820. DOI.
  • Malavaud B; Pchejetski D; Mazerolles C; Calvet C; Doumerc N; Pitson S; Rischmann P; Cuvillier O. (Oct 2008). Correlation between sphingosine kinase-1 oncogene activity and the tumoral grade of prostatic tissues removed from radical prostatectomy. B CANCER. 95:S20-S21.
  • Pchejetski D; Doumerc N; Golzio M; Naymark M; Teissie J; Kohama T; Waxman J; Malavaud B; et alCuvillier O. (Jul 2008). Chemosensitizing effects of sphingosine kinase-1 inhibition in prostate cancer cell and animal models. MOL CANCER THER. 7:1836-1845. DOI.
  • Gomez-Brouchet A; Pchejetski D; Brizuela L; Garcia V; Altié MF; Maddelein ML; Delisle MB; Cuvillier O. (Aug 2007). Critical role for sphingosine kinase-1 in regulating survival of neuroblastoma cells exposed to amyloid-beta peptide. Mol Pharmacol. 72:341-349. DOI.
  • Taurin S; Dulin NO; Pchejetski D; Grygorczyk R; Tremblay J; Hamet P; Orlov SN. (15 Sep 2002). c-Fos expression in ouabain-treated vascular smooth muscle cells from rat aorta: evidence for an intracellular-sodium-mediated, calcium-independent mechanism. J Physiol. 543:835-847.
  • Pchejetski D; Taurin S; Der Sarkissian S; Lopina OD; Pshezhetsky AV; Tremblay J; deBlois D; Hamet P; et alOrlov SN. (14 Feb 2003). Inhibition of Na+,K+-ATPase by ouabain triggers epithelial cell death independently of inversion of the [Na+]i/[K+]i ratio. Biochem Biophys Res Commun. 301:735-744.
  • Orlov SN; Pchejetski DV; Sarkissian SD; Adarichev V; Taurin S; Pshezhetsky AV; Tremblay J; Maximov GV; et aldeBlois D; Bennett MR; Hamet P. (Mar 2003). [3H]-thymidine labelling of DNA triggers apoptosis potentiated by E1A-adenoviral protein. Apoptosis. 8:199-208.
  • Brindikova TA; Bourcier N; Torres B; Pchejetski D; Gekle M; Maximov GV; Montminy V; Insel PA; et alOrlov SN; Isenring P. (Dec 2003). Purinergic-induced signaling in C11-MDCK cells inhibits the secretory Na-K-Cl cotransporter. Am J Physiol Cell Physiol. 285:C1445-C1453. DOI.
  • Orlov SN; Pchejetski D; Taurin S; Thorin-Trescases N; Maximov GV; Pshezhetsky AV; Rubin AB; Hamet P. (Jan 2004). Apoptosis in serum-deprived vascular smooth muscle cells: evidence for cell volume-independent mechanism. Apoptosis. 9:55-66. DOI.
  • Orlov SN; Thorin-Trescases N; Pchejetski D; Taurin S; Farhat N; Tremblay J; Thorin E; Hamet P. (Jun 2004). Na+/K+ pump and endothelial cell survival: [Na+]i/[K+]i-independent necrosis triggered by ouabain, and protection against apoptosis mediated by elevation of [Na+]i. Pflugers Arch. 448:335-345. DOI.
  • Le Scolan E; Pchejetski D; Banno Y; Denis N; Mayeux P; Vainchenker W; Levade T; Moreau-Gachelin F. (1 Sep 2005). Overexpression of sphingosine kinase 1 is an oncogenic event in erythroleukemic progression. Blood. 106:1808-1816. DOI.
  • Akimova OA; Pchejetski D; Hamet P; Orlov SN. (Jan 2006). Modest intracellular acidification suppresses death signaling in ouabain-treated cells. Pflugers Arch. 451:569-578. DOI.
  • Bonhoure E; Pchejetski D; Aouali N; Morjani H; Levade T; Kohama T; Cuvillier O. (Jan 2006). Overcoming MDR-associated chemoresistance in HL-60 acute myeloid leukemia cells by targeting sphingosine kinase-1. Leukemia. 20:95-102. DOI.
  • Pchejetski D; Golzio M; Bonhoure E; Calvet C; Doumerc N; Garcia V; Mazerolles C; Rischmann P; et alTeissié J; Malavaud B; Cuvillier O. (15 Dec 2005). Sphingosine kinase-1 as a chemotherapy sensor in prostate adenocarcinoma cell and mouse models. Cancer Res. 65:11667-11675. DOI.
  • Pchejetski D; Kunduzova O; Dayon A; Calise D; Seguelas MH; Leducq N; Seif I; Parini A; et alCuvillier O. (5 Jan 2007). Oxidative stress-dependent sphingosine kinase-1 inhibition mediates monoamine oxidase A-associated cardiac cell apoptosis. Circ Res. 100:41-49. DOI.

Chapters in books

  • Cuvillier O; Bonhoure E; Dayon A; Martin C; Malavaud B; Pchejetski D; Rischmann P. The ceramide/sphingosine 1-phosphate biostat in cancer and the role of sphingosine kinase-1 as a therapeutic target. In Sphingolipids and cell function. Albi E (ed). Transworld Research Network, Trivandrum (2006).
Share this on DeliciousTweet thisDigg thisStumble thisShare this on Facebook